Advanced search
Publication Cover
Neurodegenerative Disease Management Volume 9, 2019 - Issue 5
Submit an article Journal homepage
151
Views
0
CrossRef citations to date
0
Altmetric
Editorial

5-HT3 Receptors in Parkinson’s Disease Psychosis: A Forgotten Target?

Cynthia Kwan1 Neurodegenerative Disease Group Montreal Neurological Institute H3A 2B4 MontrealQCCanadaORCID Iconhttps://orcid.org/0000-0002-3878-6745
ORCID Icon &
Philippe Huot1 Neurodegenerative Disease Group Montreal Neurological Institute H3A 2B4 MontrealQCCanada;2 Department of Neurology & Neurosurgery McGill University H3A 2B4 MontrealQCCanada;3 Department of Neuroscience McGill University Health Centre H3A 2B4 MontrealQCCanadaCorrespondence[email protected]
Pages 251-253 | Received 15 Jul 2019, Accepted 31 Jul 2019, Published online: 03 Oct 2019

References

  • Hely MA , ReidWG, AdenaMA, HallidayGM, MorrisJG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov. Disord., 23(6), 837–844 (2008).
  • Pagonabarraga J , Martinez-HortaS, Fernándezde Bobadilla Ret al. Minor hallucinations occur in drug-naive Parkinson’s disease patients, even from the premotor phase. Mov. Disord., 31(1), 45–52 (2016).
  • Fernandez HH , AarslandD, FenelonGet al. Scales to assess psychosis in Parkinson’s disease: critique and recommendations. Mov. Disord., 23(4), 484–500 (2008).
  • Zahodne LB , FernandezHH. Parkinson’s psychosis. Curr. Treat. Options Neurol., 12(3), 200–211 (2010).
  • Chang A , FoxSH. Psychosis in Parkinson’s disease: epidemiology, pathophysiology, and management. Drugs, 76(11), 1093–1118 (2016).
  • Taddei RN , CankayaS, DhaliwalS, ChaudhuriKR. Management of sychosis in Parkinson’s. Parkinsons Dis., 2017, 3256542 (2017).
  • The Lancet Neurology . Difficult choices in treating Parkinson’s disease psychosis. Lancet Neurol., 17(7), 569 (2018).
  • Fenelon G . Psychosis in Parkinson’s disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr., 13(3 Suppl. 4), 18–25 (2008).
  • Nichols DE , NicholsCD. Serotonin receptors. Chem. Rev., 108(5), 1614–1641 (2008).
  • van Wijngaarden I , TulpMT, SoudijnW. The concept of selectivity in 5-HT receptor research. Eur. J. Pharmacol., 188(6), 301–312 (1990).
  • Zoldan J , FriedbergG, Goldberg-SternH, MelamedE. Ondansetron for hallucinosis in advanced Parkinson’s disease. Lancet, 341(8844), 562–563 (1993).
  • Zoldan J , FriedbergG, LivnehM, MelamedE. Psychosis in advanced Parkinson’s disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology, 45(7), 1305–1308 (1995).
  • Zoldan J , FriedbergG, WeizmanA, MelamedE. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson’s disease. Adv. Neurol., 69, 541–544 (1996).
  • Friedberg G , ZoldanJ, WeizmanA, MelamedE. Parkinson psychosis rating scale: a practical instrument for grading psychosis in Parkinson’s disease. Clin. Neuropharmacol., 21(5), 280–284 (1998).
  • Melamed E , FriedbergG, ZoldanJ. Psychosis: impact on the patient and family. Neurology, 52(7 Suppl. 3), S14–S16 (1999).
  • Onofrj M , ThomasA, BonanniL. New approaches to understanding hallucinations in Parkinson’s disease: phenomenology and possible origins. Expert Rev. Neurother., 7(12), 1731–1750 (2007).
  • Kazunori O , NobuoS, AkiraS, AtsushiN, ShuheiY, ShotaiK. [The effects of ondansetron, a 5-HT3 receptor antagonist, on medication-induced hallucinations in Parkinson’s disease]. Neurol. Ther., 16(5), 647–651 (1999).
  • Eichhorn TE , BruntE, OertelWH. Ondansetron treatment of L-dopa-induced Psychosis. Neurology, 47(6), 1608–1609 (1996).
  • Machu TK . Therapeutics of 5-HT3 receptor antagonists: current uses and future directions. Pharmacol. Ther., 130(3), 338–347 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.